Analysis of Safety from a Human Clinical Trial with Pterostilbene

Table 2

Self-reported adverse drug reactions (ADRs)^a.

	𝑛	ADRs reported (%)	𝑃 value; (versus placebo)	Type of ADR (#)
Any pterostilbene	60	10 (16.7)	0.72	—
High-dose pterostilbene	20	5 (25)	0.42	Gastrointestinal (2); Increased appetite (2); Itching (1)
Low-dose pterostilbene	20	3 (15)	1.00	Muscle pain (2); Increased appetite (1)
Low-dose + grape extract	20	2 (10)	1.00	Muscle pain (1); Increased appetite (1)
Placebo	20	2 (10)	—	Gastrointestinal (1); Itching (1)

 ^aIntention-to-treat population evaluated.